481 related articles for article (PubMed ID: 26876786)
21. Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate.
Joseph J; Wajapeyee N; Somasundaram K
Int J Cancer; 2005 May; 115(1):11-8. PubMed ID: 15688418
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
24. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
25. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
26. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Kou X; Yang Y; Jiang X; Liu H; Sun F; Wang X; Liu L; Liu H; Lin Z; Jiang L
Eur J Pharmacol; 2017 Oct; 813():161-171. PubMed ID: 28826913
[TBL] [Abstract][Full Text] [Related]
27. Syntaxin 1A Gene Is Negatively Regulated in a Cell/Tissue Specific Manner by YY1 Transcription Factor, Which Binds to the -183 to -137 Promoter Region Together with Gene Silencing Factors Including Histone Deacetylase.
Nakayama T; Fukutomi T; Terao Y; Akagawa K
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33498722
[TBL] [Abstract][Full Text] [Related]
28. miR-5590-3p-YY1 feedback loop promotes the proliferation and migration of triple-negative breast cancer cells.
Liang F; Fu X; Wang L
J Cell Biochem; 2019 Oct; 120(10):18415-18424. PubMed ID: 31190375
[TBL] [Abstract][Full Text] [Related]
29. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA.
Cheng HT; Hung WC
Oncol Rep; 2013 Aug; 30(2):961-7. PubMed ID: 23754070
[TBL] [Abstract][Full Text] [Related]
31. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
32. Negative regulation of bcl-2 expression by p53 in hematopoietic cells.
Wu Y; Mehew JW; Heckman CA; Arcinas M; Boxer LM
Oncogene; 2001 Jan; 20(2):240-51. PubMed ID: 11313951
[TBL] [Abstract][Full Text] [Related]
33. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
34. Effects of trichostatin A on HDAC8 expression, proliferation and cell cycle of Molt-4 cells.
He J; Liu H; Chen Y
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):531-3. PubMed ID: 17219959
[TBL] [Abstract][Full Text] [Related]
35. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
38. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.
Kim JY; Han SY; Yoo J; Kim GW; Jeon YH; Lee SW; Park J; Kwon SH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955780
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
40. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]